Can-Fite BioPharma CANF
NYSE CANF
$3.42 +0.02 (+0.59%)
At close: Aug 20, 2026 · 4:00 PM EDT

Can-Fite BioPharma (CANF) Cash from Operations (2013)

Can-Fite BioPharma's (CANF) quarterly Cash from Operations came in at 1701000.0 in Q3 2013.

Can-Fite BioPharma (CANF) Cash from Operations (2013) Analysis & Trends

Can-Fite BioPharma (CANF) has 1 years of Cash from Operations data on file, last reported at 1701000.0 in Q3 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn 1.13 Bn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 813.00 Mn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn -
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn -526.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 462.82 Mn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn 326.72 Mn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn -88.83 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn - 728.46 Mn
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn 360.27 Mn
10 Can-Fite BioPharma 2.82 Mn -8.73 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2013 -1.70 Mn
Sep 30, 2013 -1.70 Mn